ストックスクリーナーアプリを入手
8.22
7.33%
-0.65
アフターアワーズ：
8.23
0.010
+0.12%
前日終値:
$8.87
開ける：
$8.92
24時間の取引高:
12.80M
Relative Volume:
0.93
時価総額：
$8.61B
収益：
$140.98M
当期純損益:
$-854.60M
株価収益率:
-9.6253
EPS:
-0.854
ネットキャッシュフロー:
$-299.31M
1週間 パフォーマンス:
-12.92%
1か月 パフォーマンス:
+17.77%
6か月 パフォーマンス:
+252.79%
1年 パフォーマンス:
+186.41%
1日の値動き範囲:
$8.05
$8.92
1週間の範囲:
$8.05
$9.53
52週間の値動き範囲:
$1.95
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Compare IBRX vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
8.22 | 9.29B | 140.98M | -854.60M | -299.31M | -0.854 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 126.01B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 70.03B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 56.56B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 40.63B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-12 | 再開されました | BTIG Research | Buy |
| 2025-05-20 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-10 | 開始されました | BTIG Research | Buy |
| 2023-05-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | 開始されました | Jefferies | Buy |
すべてを表示
Immunitybio Inc (IBRX) 最新ニュース
IBRX Stock Steadies As Director Cheryl Cohen Unloads Shares - StocksToTrade
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout - 24/7 Wall St.
Can IBRX Stock Keep Its Pulse? Institutional Investors Buy In, Retail Hopes For Big Q2 Surprise - TradingView
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc - The National Law Review
IBRX Stock Slips Overnight: Insider Sale Tests Retail Optimism Ahead Of FDA Growth Catalyst - Stocktwits
IBRX Stock Still A Buy After Worst Day In Over A Year? Why This Analyst Is Shrugging Off FDA Warning Letter - Stocktwits
IBRX Stock Down 10% This Week, But Its CEO Just Outlined 3 Reasons Bull Case Is Intact - Stocktwits
ImmunityBio Deadline Today: Rosen Law Firm Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmIBRX - AOL.com
IBRX Stock Price Prediction 2025-2026 | Immunitybio Inc Forecast - 24/7 Wall St.
ImmunityBio’s Q4 Revenue Gets A Lift From ANKTIVA Sales – IBRX Stock Gains 11% - Stocktwits
ImmunityBio Insider Sold Shares Worth $1,246,941, According to a Recent SEC Filing - Moomoo
ImmunityBio Stock: A Long-Term Bull Case Worth Watching (NASDAQ:IBRX) - Seeking Alpha
ImmunityBio Insider Sold Shares Worth $1,439,066, According to a Recent SEC Filing - marketscreener.com
IBRX Stock Climbs Overnight: ImmunityBio Declares ‘All Systems Go’ For Dunkirk Anktiva Manufacturing Push - Stocktwits
Form 4 Immunitybio Inc For: 6 July By Investing.com - Investing.com Canada
ImmunityBio (IBRX) director sells 159,478 shares under 10b5-1 plan - Stock Titan
ImmunityBio director Cheryl Cohen sells $1.25m in stock - Investing.com
ImmunityBio director Cheryl Cohen sells $1.25m in stock By Investing.com - Investing.com Canada
ImmunityBio director Selecky sells $1.44m in shares By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ImmunityBio, Inc. (IBRX) And Encourages Investors to Reach Out - ACCESS Newswire
ImmunityBio (IBRX) Is Up 8.4% After Russell Index Removal Amid Anktiva Expansion EffortsWhat's Changed - simplywall.st
ImmunityBio (NASDAQ:IBRX) Screens as a High-Growth Momentum Stock Passing Minervini’s Trend Template - ChartMill
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ImmunityBio, Inc. (IBRX) And Encourages Stockholders to Reach Out - ACCESS Newswire
Form 144 shows proposed sale of 55,979 shares by Morgan Stanley (IBRX) - Stock Titan
IBRXImmunityBio Inc Revenue Breakdown - Finviz
Director Christobel Selecky Sells 96,722 Shares of ImmunityBio I - GuruFocus
Form 144 IMMUNITYBIO For: 1 July By Investing.com - Investing.com Canada
Form 4 Immunitybio Inc For: 1 July By Investing.com - Investing.com Canada
ImmunityBio director Selecky sells $871k in stock - Investing.com
ImmunityBio director Selecky sells $871k in stock By Investing.com - Investing.com Canada
Immunitybio Insider Sold Shares Worth $871,216, According to a Recent SEC Filing - marketscreener.com
ImmunityBio (IBRX) director pre-plans option exercises and sells 96,722 shares - Stock Titan
Insider files Form 144: IBRX (NASDAQ: IBRX) plans sale of 159,478 shares - Stock Titan
ImmunityBio Founder Pushes Back After FDA Warning Letter Over Anktiva Claims — Says Ad 'Never Aired At All' - Stocktwits
IBRX (NASDAQ) insider exercise 1,000 shares; 95,722-share 10b5-1 sale - Stock Titan
IBRX Stock Surges 12% On Russell 1000 Inclusion Hopes - Stocktwits
IBRX Stock Eyes Best Week Since February: Founder Highlights New Anktiva-NK Cell Therapy Study - Stocktwits
IBRX Stock At 3-Month High: Retail Bulls Eye July Catalysts Around Anktiva Saudi Expansion, Q2 Sales - Stocktwits
[144] ImmunityBio, Inc. SEC Filing - Stock Titan
ImmunityBio, Inc.(NasdaqGS: IBRX) dropped from Russell 2000 Value Benchmark - marketscreener.com
IBRX Stock Is Back: Anktiva Now Targets Severe Pneumonia After Clearing Key Checkpoint In Bladder Cancer Trial - Stocktwits
ImmunityBio (IBRX) Moves 11.8% Higher: Will This Strength Last? - Yahoo Finance
Enterprise value to revenue forward of ImmunityBio, Inc. – NASDAQ:IBRX - TradingView
SLS, IBRX Eye Green Month As Biotech ETF Gains Steam: Analyst Sees ‘Continued Opportunities’ In Immuno-Oncology - Stocktwits
IBRX Stock Lights Up: Retail Cheers Calls For Trump To ‘Pull The Plug’ On FDA Chief Marty Makary Amid Anktiva Row - Stocktwits
Enterprise value to revenue forward of ImmunityBio Inc – TRADEGATE:26CA - TradingView
ImmunityBio, Inc.(NasdaqGS: IBRX) dropped from Russell 3000E Value Benchmark - marketscreener.com
IBRX Stock In Spotlight: ImmunityBio To Unveil Fresh Anktiva And BCG Data Next Week - Stocktwits
ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
IBRX Stock In Spotlight As FDA Scrutiny Prompts ImmunityBio To Withdraw Content, Tighten Oversight - Stocktwits
Immunitybio Inc (IBRX) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):